ArticleAnnals of Indian Academy of Neurology2026
Clinical Presentation and Evolution of Isolated Focal and Segmental Dystonia in Adults - 20 Years' Experience from a Botulinum Toxin Clinic.
Article in Annals of Indian Academy of Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIsolated dystonia generally occurs due to genetic causes, and the pattern and distribution may change over time. Botulinum toxin is the first-line treatment in those with isolated focal and segmental dystonia. We aimed to describe the clinical profile and evolution of adult patients with isolated focal and segmental dystonia presenting for treatment in our botulinum neurotoxin (BoNT) clinic, and the response to treatment, over 20 years.
methodsWe retrospectively reviewed the medical records of patients with isolated focal and segmental dystonia who had at least two visits in our BoNT clinic. The clinical features at presentation and during follow-up, muscles injected for each type of dystonia, the self-reported benefit with BoNT, and adverse effects were analyzed.
resultsFive hundred seventy-eight patients with isolated dystonia were injected and had at least one additional follow-up. Five hundred seventeen (89.4%) had focal dystonia, and 61 (10.6%) had segmental dystonia. Cervical dystonia was the most common type. Spread to other regions was seen in 81 (14%) of patients. Those with blepharospasm as initial presentation tended to have the highest occurrence (27.3%) of spread to other parts. The mean response to BoNT was around 68%. The presence of a sensory trick and the absence of tremor were found to be predictors of good outcomes with BoNT.
conclusionsIsolated focal and segmental dystonia in adults has a good prognosis, with the majority responding well to BoNT and the dystonia remaining confined to the initially affected body part. Our study provides evidence for the response to BoNT therapy in a real-world scenario, outside of a clinical trial setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.